SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report)‘s stock had its “buy” rating reiterated by BTIG Research in a note issued to investors on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock. BTIG Research’s target price would indicate a potential upside of 63.93% from the company’s current price.
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and an average target price of $7.50.
Read Our Latest Stock Analysis on SOPHiA GENETICS
SOPHiA GENETICS Stock Performance
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The business had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million.
Insider Buying and Selling at SOPHiA GENETICS
In other news, CEO Jurgi Camblong sold 43,129 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $4.96, for a total transaction of $213,919.84. Following the completion of the sale, the chief executive officer owned 3,664,440 shares in the company, valued at $18,175,622.40. This represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 207,359 shares of company stock valued at $1,013,067. Company insiders own 4.88% of the company’s stock.
Hedge Funds Weigh In On SOPHiA GENETICS
Several institutional investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after buying an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of SOPHiA GENETICS by 16.4% in the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after acquiring an additional 31,000 shares in the last quarter. Akre Capital Management LLC increased its stake in shares of SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the period. Savvy Advisors Inc. acquired a new position in shares of SOPHiA GENETICS during the third quarter worth about $48,000. Finally, GSA Capital Partners LLP purchased a new position in SOPHiA GENETICS during the third quarter worth about $59,000. 31.59% of the stock is owned by institutional investors and hedge funds.
SOPHiA GENETICS Company Profile
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Stories
- Five stocks we like better than SOPHiA GENETICS
- Qualcomm Drops 25%, But Investor Day Could Reverse the Slide
- Meta to Follow Alphabet’s Footsteps? What an Equity Raise Could Mean
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
